TY - JOUR
T1 - Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE)
T2 - a prospective, multinational study
AU - European Survey of Carbapenemase-Producing Enterobacteriaceae (EuSCAPE) working group
AU - Grundmann, Hajo
AU - Glasner, Corinna
AU - Albiger, Barbara
AU - Aanensen, David M.
AU - Tomlinson, Chris T.
AU - Andrasević, Arjana Tambić
AU - Cantón, Rafael
AU - Carmeli, Yehuda
AU - Friedrich, Alexander W.
AU - Giske, Christian G.
AU - Glupczynski, Youri
AU - Gniadkowski, Marek
AU - Livermore, David M.
AU - Nordmann, Patrice
AU - Poirel, Laurent
AU - Rossolini, Gian M.
AU - Seifert, Harald
AU - Vatopoulos, Alkiviadis
AU - Walsh, Timothy
AU - Woodford, Neil
AU - Monnet, Dominique L.
AU - Apfalter, Petra
AU - Hartl, Rainer
AU - Glupczynski, Youri
AU - Huang, Te Din
AU - Strateva, Tanya
AU - Marteva-Proevska, Yuliya
AU - Andraševic, Arjana Tambic
AU - Butic, Iva
AU - Pieridou-Bagatzouni, Despo
AU - Maikanti-Charalampous, Panagiota
AU - Hrabak, Jaroslav
AU - Zemlickova, Helena
AU - Hammerum, Anette
AU - Jakobsen, Lotte
AU - Ivanova, Marina
AU - Pavelkovich, Anastasia
AU - Jalava, Jari
AU - Österblad, Monica
AU - Vaux, Sophie
AU - Dortet, Laurent
AU - Kaase, Martin
AU - Gatermann, Sören G.
AU - Vatopoulos, Alkiviadis
AU - Tryfinopoulou, Kyriaki
AU - Tóth, Ákos
AU - Jánvári, Laura
AU - Boo, Teck Wee
AU - Carmeli, Yehuda
AU - Adler, Amos
N1 - Publisher Copyright:
© 2017 Elsevier Ltd
PY - 2017/2/1
Y1 - 2017/2/1
N2 - Background Gaps in the diagnostic capacity and heterogeneity of national surveillance and reporting standards in Europe make it difficult to contain carbapenemase-producing Enterobacteriaceae. We report the development of a consistent sampling framework and the results of the first structured survey on the occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in European hospitals. Methods National expert laboratories recruited hospitals with diagnostic capacities, who collected the first ten carbapenem non-susceptible clinical isolates of K pneumoniae or E coli and ten susceptible same-species comparator isolates and pertinent patient and hospital information. Isolates and data were relayed back to national expert laboratories, which made laboratory-substantiated information available for central analysis. Findings Between Nov 1, 2013, and April 30, 2014, 455 sentinel hospitals in 36 countries submitted 2703 clinical isolates (2301 [85%] K pneumoniae and 402 (15%) E coli). 850 (37%) of 2301 K pneumoniae samples and 77 (19%) of 402 E coli samples were carbapenemase (KPC, NDM, OXA-48-like, or VIM) producers. The ratio of K pneumoniae to E coli was 11:1. 1·3 patients per 10000 hospital admissions had positive clinical specimens. Prevalence differed greatly, with the highest rates in Mediterranean and Balkan countries. Carbapenemase-producing K pneumoniae isolates showed high resistance to last-line antibiotics. Interpretation This initiative shows an encouraging commitment by all participants, and suggests that challenges in the establishment of a continent-wide enhanced sentinel surveillance for carbapenemase-producing Enterobacteriaeceae can be overcome. Strengthening infection control efforts in hospitals is crucial for controlling spread through local and national health care networks. Funding European Centre for Disease Prevention and Control.
AB - Background Gaps in the diagnostic capacity and heterogeneity of national surveillance and reporting standards in Europe make it difficult to contain carbapenemase-producing Enterobacteriaceae. We report the development of a consistent sampling framework and the results of the first structured survey on the occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in European hospitals. Methods National expert laboratories recruited hospitals with diagnostic capacities, who collected the first ten carbapenem non-susceptible clinical isolates of K pneumoniae or E coli and ten susceptible same-species comparator isolates and pertinent patient and hospital information. Isolates and data were relayed back to national expert laboratories, which made laboratory-substantiated information available for central analysis. Findings Between Nov 1, 2013, and April 30, 2014, 455 sentinel hospitals in 36 countries submitted 2703 clinical isolates (2301 [85%] K pneumoniae and 402 (15%) E coli). 850 (37%) of 2301 K pneumoniae samples and 77 (19%) of 402 E coli samples were carbapenemase (KPC, NDM, OXA-48-like, or VIM) producers. The ratio of K pneumoniae to E coli was 11:1. 1·3 patients per 10000 hospital admissions had positive clinical specimens. Prevalence differed greatly, with the highest rates in Mediterranean and Balkan countries. Carbapenemase-producing K pneumoniae isolates showed high resistance to last-line antibiotics. Interpretation This initiative shows an encouraging commitment by all participants, and suggests that challenges in the establishment of a continent-wide enhanced sentinel surveillance for carbapenemase-producing Enterobacteriaeceae can be overcome. Strengthening infection control efforts in hospitals is crucial for controlling spread through local and national health care networks. Funding European Centre for Disease Prevention and Control.
UR - http://www.scopus.com/inward/record.url?scp=85006957610&partnerID=8YFLogxK
U2 - 10.1016/S1473-3099(16)30257-2
DO - 10.1016/S1473-3099(16)30257-2
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 27866944
AN - SCOPUS:85006957610
SN - 1473-3099
VL - 17
SP - 153
EP - 163
JO - The Lancet Infectious Diseases
JF - The Lancet Infectious Diseases
IS - 2
ER -